Intravitreal tenecteplase (Metalyse) for acute management of retinal vein occlusions

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 7, 2013, Pages 4910-4918

  McAllister, Ian L ^a   Vijayasekaran, Sarojini ^a   Yu, Dao Yi ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BRVO; TNK; Vitreoretinal surgery

Indexed keywords

CHLORAMPHENICOL; EPOXY RESIN; TENECTEPLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; CELL ULTRASTRUCTURE; CONTROLLED STUDY; EPIFLUORESCENCE MICROSCOPY; ERYTHROCYTE; HISTOLOGY; LASER; LASER COAGULATION; MICROSCOPY; NONHUMAN; OPHTHALMOSCOPY; OPTIC DISK; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA VEIN; RETINA VEIN OCCLUSION; SWELLING; SWINE; THROMBUS; TRANSMISSION ELECTRON MICROSCOPY; VITRECTOMY;

BRVO; TNK; VITREORETINAL SURGERY;

ACUTE DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INTRAVITREAL INJECTIONS; RETINAL VEIN; RETINAL VEIN OCCLUSION; SWINE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84880695692     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11967     Document Type: Article

References (49)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-141.
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114:1243-1247.
3. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.
4. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513-518.
5. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271-282.
6. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1094-1101.
7. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363:2135-2144.
8. Baglivo E, Dosso A, Pournaras C. Thrombus and branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1997;235: 10-13.
9. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100:1132-1140.
10. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105:424-427.
11. Beaumont PE, Kang HK. Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol. 2000;118:1357-1363.
12. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371-422.
13. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24: 493-519.
14. Cahill MT, Kaiser PK, Sears JE, Fekrat S. The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2003;87:1329-1332.
15. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E. Longterm outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina. 2007; 27:49-54.
16. Le Rouic JF, Bejjani RA, Rumen F, et al. Adventitial sheathotomy for decompression of recent onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2001;239:747-751.
17. Mason J III, Feist R, White M Jr, Swanner J, McGwin G Jr, Emond T. Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology. 2004; 111:540-545.
18. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina. 1999;19:1-5.
19. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol. 1988;106:1469-1471.
20. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2004;138:907-914.
21. Bynoe LA, Hutchins RK, Lazarus HS, Friedberg MA. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina. 2005;25:625-632.
22. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, Blasco H, Corcostegui B. Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina. 2004;24:530-540.
23. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000;84:609-613.
24. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999;30:427-434.
25. Murakami T, Takagi H, Kita M, et al. Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;142: 318-320.
26. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology. 2001;108:2249-2257.
27. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol. 1999;128: 739-746.
28. Mahmoud TH, Peng YW, Proia AD, Davidson M, Deramo VA, Fekrat S. Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion. Br J Ophthalmol. 2006; 90:911-915.
29. Kwan AS, Vijayasekaran S, McAllister IL, Yu PK, Yu DY. A study of retinal penetration of intravitreal tenecteplase in pigs. Invest Ophthalmol Vis Sci. 2006;47:2662-2667.
30. McAllister IL, Vijayasekaran S, Khong CH, Yu DY. Investigation of the safety of tenecteplase to the outer retina. Clin Experiment Ophthalmol. 2006;34:787-793.
31. Rowley SA, Vijayasekaran S, Yu PK, McAllister IL, Yu DY. Retinal toxicity of intravitreal tenecteplase in the rabbit. Br J Ophthalmol. 2004;88:573-578.
32. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147:838-846.
33. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114:835-854.
34. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
35. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.
36. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology. 2010;117:1102-1112.
37. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594-1602.
38. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 1986;104:34-41.
39. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119: 802-809.
40. Pieris SJ, Hill DW. Collateral vessels in branch retinal vein occlusion. Trans Ophthalmol Soc U K. 1982;102(pt 1):178-181.
41. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938-949.
42. Nurden AT. Human platelet membrane glycoproteins. In: Bloom AL, ed. Hemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1994:115-166.
43. McAllister IL, Chen SD, Patel JI, Fleming BL, Yu DY. Management of submacular haemorrhage in age-related macular degeneration with intravitreal tenecteplase. Br J Ophthalmol. 2010;94:260-261.
44. Pitkanen L, Pelkonen J, Ruponen M, Ronkko S, Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J. 2004;6:e25.
45. Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol. 2000;118: 659-663.
46. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1990;108:259-263.
47. Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology. 2003;110:704-708.
48. Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther. 2001; 23:982-997.
49. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart. 2003;89:1358-1362.